This from a private briefing note, ds posted on 15/02/16....

This from a private briefing note, ds posted on 15/02/16. Particularly read the last paragraph.

2. Understanding Phylogica’s true source of advantage

Phylogica’s approach to intracellular delivery of large molecules relies on a drug having four properties. Phylogica has adopted a modular approach to drug development where each of these four properties is conferred by a discrete module of a broader drug compound. The four properties are:

1) the ability to target a particular cell type within the body for delivery of the drug

2) the ability to cross the cell membrane and be active within the cell’s cytoplasm

3) the ability to interact with a target inside the cell in a way that beneficially changes the behaviour of that cell

4) the ability to protect the drug between the site of administration (typically a vein) and the site of action (a tumour in Phylogica’s case)

Phylogica has distinctive capabilities in contributing the two modules directed towards properties 2 and 3. These are the two most unique elements of the drug compound.Properties 1 and 4 are more generic problems and have been addressed by a variety of groups through a number of different approaches. Phylogica can license the technologies best suited to its Phylomer platform for inclusion in a lead compound.
....
This is also in the last shareholder update but the last para is different.

http://www.aspectfinancial.com.au/d...zaWduYWwvZXJyb3JwYWdlcy9wZGZkZWxheWVkLmpzcA==

I suspect nano drug delivery systems (nano capsules, liposomes etc) will be licenced to do 1) and 2) where capabilities are required.
Sot